Suppr超能文献

[根据世界卫生组织标准,硝苯地平和维拉帕米短期治疗对I度原发性高血压患者血压、血浆心钠素(ANP)和环磷酸鸟苷(cGMP)的影响比较]

[Comparison of the effect of short-term treatment with nifedipine and verapamil on blood pressure, plasma atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) in patients with primary arterial hypertension I degree according to WHO].

作者信息

Widecka K, Marzecka J, Goździk J, Gruszczyńska M, Ciechanowski K, Czekalski S

机构信息

Kliniki Endokrynologii i Chorób Przemiany Materii PAM, Szczecinie.

出版信息

Pol Tyg Lek. 1994;49(10-11):228-30.

PMID:7862584
Abstract

The aim of the study was the comparison of the effect of seven day treatment with nifedipine (2 x 10 mg daily) and subsequently with verapamil (3 x 40 mg daily) on blood pressure, heart rate, plasma ANP, cGMP, renin activity (PRA), aldosterone (ALDO) concentrations in patients with primary hypertension. The material consisted of 12 untreated patients with primary arterial hypertension Io WHO. These results suggest that short-term treatment with nifedipine and subsequently with verapamil in patients with primary hypertension Io WHO not influence on plasma ANP, cGMP, PRA and ALDO in spite of blood pressure reduction and the changes in heart rate. It seems that ANP did not participate in hypotensive action of nifedipine and verapamil. No augmentation of urinary sodium excretion was found after short-term treatment with nifedipine or verapamil.

摘要

本研究的目的是比较硝苯地平(每日2次,每次10毫克)治疗7天,随后维拉帕米(每日3次,每次40毫克)治疗对原发性高血压患者血压、心率、血浆心钠素(ANP)、环磷酸鸟苷(cGMP)、肾素活性(PRA)、醛固酮(ALDO)浓度的影响。研究材料包括12例未经治疗的世界卫生组织(WHO)原发性动脉高血压患者。这些结果表明,对于WHO原发性高血压患者,短期使用硝苯地平并随后使用维拉帕米治疗,尽管血压降低且心率有变化,但对血浆ANP、cGMP、PRA和ALDO没有影响。似乎心钠素不参与硝苯地平和维拉帕米的降压作用。短期使用硝苯地平或维拉帕米治疗后,未发现尿钠排泄增加。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验